Granted Patent
B2
US 12,600,772 · App. 16/963,311 · Granted Apr 14, 2026
Therapeutic agent for asthma containing IL-6 inhibitor
Assignee:
Motokazu Kato
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides therapeutic agents for treating human asthma through administration of an IL-6 inhibitor to humans. Representative IL-6 inhibitors in the present invention include IL-6 receptor antibodies and IL-6 antibodies. Therapeutic agents of the present invention can yield therapeutic effects in severe asthma patients who need administration of high-dose steroids and such for alleviation of symptoms, or even in patients whose symptoms are difficult to control by common treatment.
Claims (16)
1 . A method for treating human severe non-eosinophilic asthma, comprising administering 162 mg of an anti-IL-6 receptor antibody to a human adult subject in need thereof, wherein the anti-IL-6 receptor antibody is tocilizumab.
2 . The method of claim 1 , wherein tocilizumab comprises:
a) the heavy chain variable region of SEQ ID NO: 1 and the light chain variable region of SEQ ID NO: 2; or
b) the heavy chain variable region of SEQ ID NO: 5 and the light chain variable region of SEQ ID NO: 6.
3 . The method of claim 1 , wherein tocilizumab comprises:
a) the heavy chain of SEQ ID NO: 3 and the light chain of SEQ ID NO: 4, or
b) the heavy chain of SEQ ID NO: 7 and the light chain of SEQ ID NO: 8.
4 . The method of claim 1 , wherein the blood C-reactive protein (CRP) of the subject administered the anti-IL-6 receptor antibody is above normal level.
5 . The method of claim 1 , wherein the subject has rheumatoid arthritis.
6 . The method of claim 1 , wherein the administration results in:
suppression of at least one asthmatic symptom in the subject selected from coughing, wheezing, expectoration, and dyspnea;
a) improvement of respiratory function of the subject as measured by Peak Expiratory Flow (PEF); or
b) reduction in the amount of steroid use by the subject.
7 . The method of claim 1 , wherein the administration results in an improved Asthma Control Test (ACT) score in the subject and wherein the improved ACT score is 20 or greater.
8 . The method of claim 1 , wherein the anti-IL-6 receptor antibody is administered in combination with an inhaled steroid or a systemic steroid.
9 . The method of claim 1 , wherein the anti-IL-6 receptor antibody is administered in combination with an additional long-acting β2-agonist.
Priority Claims (2)
JP 2018-015983
· Jan 31, 2018
· national
JP 2018-187251
· Oct 2, 2018
· national
Continuity (1)
References Cited (400)
US 5126250A
· Mcdonough et al.
· 1992
[cited by applicant]
US 5216128A
· Novick et al.
· 1993
[cited by applicant]
US 5530101A
· Queen et al.
· 1996
[cited by applicant]
US 5621077A
· Novick et al.
· 1997
[cited by applicant]
US 5639455A
· Shimamura et al.
· 1997
[cited by applicant]
US 5670373A
· Kishimoto
· 1997
[cited by applicant]
US 5795965A
· Tsuchiya et al.
· 1998
[cited by applicant]
US 5817790A
· Tsuchiya et al.
· 1998
[cited by applicant]
US 5856135A
· Tsuchiya et al.
· 1999
[cited by applicant]
US 5888510A
· Kishimoto et al.
· 1999
[cited by applicant]
US 6074643A
· Barbera-Guillem
· 2000
[cited by applicant]
US 6121423A
· Tsuchiya et al.
· 2000
[cited by applicant]
US 6261560B1
· Tsujinaka et al.
· 2001
[cited by applicant]
US 6309636B1
· do Couto et al.
· 2001
[cited by applicant]
US 6552083B1
· Isobe et al.
· 2003
[cited by applicant]
US 6723319B1
· Ito et al.
· 2004
[cited by applicant]
US 7291721B2
· Giles-Komar et al.
· 2007
[cited by applicant]
US 7320792B2
· Ito et al.
· 2008
[cited by applicant]
US 7414024B2
· Blay et al.
· 2008
[cited by applicant]
US 7438907B2
· Schuurman et al.
· 2008
[cited by applicant]
US 7479543B2
· Tsuchiya et al.
· 2009
[cited by applicant]
US 7521052B2
· Okuda et al.
· 2009
[cited by applicant]
US 7582298B2
· Stevens et al.
· 2009
[cited by applicant]
US 7759472B2
· Shima et al.
· 2010
[cited by applicant]
US 7781617B2
· Kudou et al.
· 2010
[cited by applicant]
US 7824674B2
· Ito et al.
· 2010
[cited by applicant]
US 7825109B2
· Nakade et al.
· 2010
[cited by applicant]
US 7884196B2
· Lawless
· 2011
[cited by applicant]
US 7935340B2
· Garcia-Martinez et al.
· 2011
[cited by applicant]
US 7955590B2
· Gillies et al.
· 2011
[cited by applicant]
US 8017121B2
· Kishimoto et al.
· 2011
[cited by applicant]
US 8226611B2
· Chen et al.
· 2012
[cited by applicant]
US 8323649B2
· Garcia-Martinez et al.
· 2012
[cited by applicant]
US 8398980B2
· Kano et al.
· 2013
[cited by applicant]
US 8470316B2
· Yasunami
· 2013
[cited by applicant]
US 8562991B2
· Igawa et al.
· 2013
[cited by applicant]
US 8580264B2
· Zhang et al.
· 2013
[cited by applicant]
US 8623355B2
· Okada et al.
· 2014
[cited by applicant]
US 8771686B2
· Ishida
· 2014
[cited by applicant]
US 8945558B2
· Kobara
· 2015
[cited by applicant]
US 9017677B2
· Mihara
· 2015
[cited by applicant]
US 9096651B2
· Igawa et al.
· 2015
[cited by applicant]
US 9260516B2
· Nishimoto et al.
· 2016
[cited by applicant]
US 9334331B2
· Igawa
· 2016
[cited by examiner]
US 9539322B2
· Nishimura
· 2017
[cited by applicant]
US 9688762B2
· Igawa et al.
· 2017
[cited by applicant]
US 9725514B2
· Takahashi et al.
· 2017
[cited by applicant]
US 20020119150A1
· Kirk et al.
· 2002
[cited by applicant]
US 20020187150A1
· Mihara et al.
· 2002
[cited by applicant]
US 20040018540A1
· Yamamura et al.
· 2004
[cited by applicant]
US 20050182007A1
· McSWIGGEN et al.
· 2005
[cited by applicant]
US 20060039902A1
· Young et al.
· 2006
[cited by applicant]
US 20060165696A1
· Okano et al.
· 2006
[cited by applicant]
US 20060193772A1
· Ochiai et al.
· 2006
[cited by applicant]
US 20060292147A1
· Yoshizaki et al.
· 2006
[cited by applicant]
US 20070036785A1
· Kishimoto et al.
· 2007
[cited by applicant]
US 20070134242A1
· Nishimoto et al.
· 2007
[cited by applicant]
US 20080081041A1
· Nemeth
· 2008
[cited by applicant]
US 20090022719A1
· Mihara et al.
· 2009
[cited by applicant]
US 20090022726A1
· Zaki et al.
· 2009
[cited by applicant]
US 20090269335A1
· Nakashima et al.
· 2009
[cited by applicant]
US 20110111406A1
· Igawa et al.
· 2011
[cited by applicant]
US 20110245473A1
· Igawa et al.
· 2011
[cited by applicant]
US 20120183539A1
· Maeda
· 2012
[cited by applicant]
US 20120253016A1
· Igawa et al.
· 2012
[cited by applicant]
US 20130274133A1
· Nielsen
· 2013
[cited by examiner]
US 20130317203A1
· Igawa et al.
· 2013
[cited by applicant]
US 20160022812A1
· Mitsunaga et al.
· 2016
[cited by applicant]
US 20170056621A1
· Stein
· 2017
[cited by examiner]
US 20170121412A1
· Igawa et al.
· 2017
[cited by applicant]
US 20170362304A1
· Fukuda et al.
· 2017
[cited by applicant]
US 20190085085A1
· Igawa et al.
· 2019
[cited by applicant]
US 20200231688A1
· Igawa et al.
· 2020
[cited by applicant]
US 20210017286A1
· Kakehi et al.
· 2021
[cited by applicant]
US 20210206862A1
· Igawa et al.
· 2021
[cited by applicant]
US 20220033489A1
· Chatila
· 2022
[cited by examiner]
US 20220041741A1
· Igawa et al.
· 2022
[cited by applicant]
US 20220220210A1
· Takeshita et al.
· 2022
[cited by applicant]
US 20220306755A1
· Igawa et al.
· 2022
[cited by applicant]
US 20230159648A1
· Igawa et al.
· 2023
[cited by applicant]
US 20240010738A1
· Igawa et al.
· 2024
[cited by applicant]
US 20240150477A1
· Kakehi et al.
· 2024
[cited by applicant]
US 20240158518A1
· Ozawa et al.
· 2024
[cited by applicant]
US 20240301075A1
· Igawa et al.
· 2024
[cited by applicant]
US 20240417480A1
· Kakehi et al.
· 2024
[cited by applicant]
AR 068564A1
· 2009
[cited by applicant]
CA 1332367C
· 1994
[cited by applicant]
CA 2203182A1
· 1996
[cited by applicant]
CA 2443294A1
· 2002
[cited by applicant]
CA 2523577A1
· 2004
[cited by applicant]
CA 2549467A1
· 2005
[cited by applicant]
CA 2560953A1
· 2005
[cited by applicant]
CA 2625773A1
· 2007
[cited by applicant]
CA 2626688A1
· 2007
[cited by applicant]
CA 2648644A1
· 2007
[cited by applicant]
CA 2700394A1
· 2009
[cited by applicant]
CA 2700498A1
· 2009
[cited by applicant]
CA 2203182C
· 2009
[cited by applicant]
CA 2549467C
· 2012
[cited by applicant]
CA 2443294C
· 2013
[cited by applicant]
CA 2700498C
· 2016
[cited by applicant]
CA 2700394C
· 2017
[cited by applicant]
CN 1164194A
· 1997
[cited by applicant]
CN 1297357A
· 2001
[cited by applicant]
CN 1694894A
· 2005
[cited by applicant]
CN 1849135A
· 2006
[cited by applicant]
CN 100374159C
· 2008
[cited by applicant]
CN 100374457C
· 2008
[cited by applicant]
CN 101849006A
· 2010
[cited by applicant]
CN 101849006B
· 2013
[cited by applicant]
CN 103476793A
· 2013
[cited by applicant]
EP 0361902A2
· 1990
[cited by applicant]
EP 0361902B1
· 1994
[cited by applicant]
EP 0628639A1
· 1994
[cited by applicant]
EP 0721783A1
· 1996
[cited by applicant]
EP 0783893A1
· 1997
[cited by applicant]
EP 0791359A1
· 1997
[cited by applicant]
EP 0811384A1
· 1997
[cited by applicant]
EP 0628639B1
· 1999
[cited by applicant]
EP 0931544A2
· 1999
[cited by applicant]
EP 0983767A1
· 2000
[cited by applicant]
EP 1004315A1
· 2000
[cited by applicant]
EP 1074268A1
· 2001
[cited by applicant]
EP 1108435A1
· 2001
[cited by applicant]
EP 1197210A1
· 2002
[cited by applicant]
EP 1334731A1
· 2003
[cited by applicant]
EP 1374900A1
· 2004
[cited by applicant]
EP 0721783B1
· 2005
[cited by applicant]
EP 1562968A1
· 2005
[cited by applicant]
EP 1197210B1
· 2005
[cited by applicant]
EP 0811384B1
· 2006
[cited by applicant]
EP 1690550A1
· 2006
[cited by applicant]
EP 1707215A1
· 2006
[cited by applicant]
EP 1728801A1
· 2006
[cited by applicant]
EP 1733740A1
· 2006
[cited by applicant]
EP 1074268B1
· 2008
[cited by applicant]
EP 1334731B1
· 2008
[cited by applicant]
EP 1004315B1
· 2008
[cited by applicant]
EP 1941907A1
· 2008
[cited by applicant]
EP 1941908A1
· 2008
[cited by applicant]
EP 0983767B1
· 2008
[cited by applicant]
EP 1967207A1
· 2008
[cited by applicant]
EP 1967209A1
· 2008
[cited by applicant]
EP 1990060A1
· 2008
[cited by applicant]
EP 2025346A1
· 2009
[cited by applicant]
EP 2123302A1
· 2009
[cited by applicant]
EP 2174667A1
· 2010
[cited by applicant]
EP 2194066A1
· 2010
[cited by applicant]
EP 2196220A1
· 2010
[cited by applicant]
EP 2202245A1
· 2010
[cited by applicant]
EP 2206775A1
· 2010
[cited by applicant]
EP 2275443A1
· 2011
[cited by applicant]
EP 2305306A1
· 2011
[cited by applicant]
EP 2330193A1
· 2011
[cited by applicant]
EP 1707215B1
· 2012
[cited by applicant]
EP 0783893B1
· 2012
[cited by applicant]
EP 1967209B1
· 2012
[cited by applicant]
EP 1690550B1
· 2012
[cited by applicant]
EP 2578233A1
· 2013
[cited by applicant]
EP 1562968B1
· 2013
[cited by applicant]
EP 2639305A1
· 2013
[cited by applicant]
EP 2196220B1
· 2014
[cited by applicant]
EP 2330193B1
· 2015
[cited by applicant]
EP 1941908B1
· 2015
[cited by applicant]
EP 2123302B1
· 2015
[cited by applicant]
EP 2275443B1
· 2015
[cited by applicant]
EP 2305306B1
· 2016
[cited by applicant]
EP 1941907B1
· 2016
[cited by applicant]
EP 3009518A1
· 2016
[cited by applicant]
EP 1967207B1
· 2016
[cited by applicant]
EP 2206775B1
· 2016
[cited by applicant]
EP 2202245B1
· 2016
[cited by applicant]
EP 2174667B1
· 2017
[cited by applicant]
EP 2578233B1
· 2017
[cited by applicant]
EP 3483283A1
· 2019
[cited by applicant]
ES 2276525T3
· 2007
[cited by applicant]
FR 2694767A1
· 1994
[cited by applicant]
FR 2694767B1
· 1994
[cited by applicant]
JP H02163096A
· 1990
[cited by applicant]
JP H06505253A
· 1994
[cited by applicant]
JP H06237772A
· 1994
[cited by applicant]
JP H0746998A
· 1995
[cited by applicant]
JP H07505609A
· 1995
[cited by applicant]
JP H08208514A
· 1996
[cited by applicant]
JP H1189582A
· 1999
[cited by applicant]
JP 2925181B2
· 1999
[cited by applicant]
JP H11180873A
· 1999
[cited by applicant]
JP 3067987B2
· 2000
[cited by applicant]
JP 2002527354A
· 2002
[cited by applicant]
JP 3345419B2
· 2002
[cited by applicant]
JP 2003525243A
· 2003
[cited by applicant]
JP 2004028926A
· 2004
[cited by applicant]
JP 3525221B2
· 2004
[cited by applicant]
JP 3614183B2
· 2005
[cited by applicant]
JP 2005524606A
· 2005
[cited by applicant]
JP 2005281235A
· 2005
[cited by applicant]
JP 2006503001A
· 2006
[cited by applicant]
JP 2006512325A
· 2006
[cited by applicant]
JP 2006524685A
· 2006
[cited by applicant]
JP 3856734B2
· 2006
[cited by applicant]
JP 2007528691A
· 2007
[cited by applicant]
JP 2008037875A
· 2008
[cited by applicant]
JP 2008037876A
· 2008
[cited by applicant]
JP 2008538931A
· 2008
[cited by applicant]
JP 2008297315A
· 2008
[cited by applicant]
JP 4468578B2
· 2010
[cited by applicant]
JP 2010527615A
· 2010
[cited by applicant]
JP 4609877B2
· 2011
[cited by applicant]
JP 4698652B2
· 2011
[cited by applicant]
JP 4763043B2
· 2011
[cited by applicant]
JP 4799516B2
· 2011
[cited by applicant]
JP 2012500020A
· 2012
[cited by applicant]
JP 4869063B2
· 2012
[cited by applicant]
JP 2013541594A
· 2013
[cited by applicant]
JP 5530635B2
· 2014
[cited by applicant]
JP 5685535B2
· 2015
[cited by applicant]
JP 5833823B2
· 2015
[cited by applicant]
KR 20060010765A
· 2006
[cited by applicant]
KR 20070035482A
· 2007
[cited by applicant]
RU 2127117C1
· 1999
[cited by applicant]
RU 2147442C1
· 2000
[cited by applicant]
RU 2195960C2
· 2003
[cited by applicant]
RU 2430111C1
· 2011
[cited by applicant]
TW 200803895A
· 2008
[cited by applicant]
TW 201021829A
· 2010
[cited by applicant]
TW 201302219A1
· 2013
[cited by applicant]
TW I440469B
· 2014
[cited by applicant]
TW 201642902A
· 2016
[cited by applicant]
WO WO9212729A1
· 1992
[cited by applicant]
WO WO9219759A1
· 1992
[cited by applicant]
WO WO9308817A1
· 1993
[cited by applicant]
WO WO9420488A1
· 1994
[cited by applicant]
WO WO9428159A1
· 1994
[cited by applicant]
WO WO9509873A1
· 1995
[cited by applicant]
WO WO9611020A1
· 1996
[cited by applicant]
WO WO9612503A1
· 1996
[cited by applicant]
WO WO9625174A1
· 1996
[cited by applicant]
WO WO9836061A2
· 1998
[cited by applicant]
WO WO9842377A1
· 1998
[cited by applicant]
WO WO9908707A1
· 1999
[cited by applicant]
WO WO9947170A1
· 1999
[cited by applicant]
WO WO9958572A1
· 1999
[cited by applicant]
WO WO9960013A2
· 1999
[cited by applicant]
WO WO0010607A1
· 2000
[cited by applicant]
WO WO0105394A1
· 2001
[cited by applicant]
WO WO0145678A2
· 2001
[cited by applicant]
WO WO0164214A2
· 2001
[cited by applicant]
WO WO0203492A1
· 2002
[cited by applicant]
WO WO0234292A1
· 2002
[cited by applicant]
WO WO02080969A1
· 2002
[cited by applicant]
WO WO03048205A2
· 2003
[cited by applicant]
WO WO03105861A1
· 2003
[cited by applicant]
WO WO2004007701A1
· 2004
[cited by applicant]
WO WO2004039826A1
· 2004
[cited by applicant]
WO WO2004045507A2
· 2004
[cited by applicant]
WO WO2004045512A2
· 2004
[cited by applicant]
WO WO2004045520A2
· 2004
[cited by applicant]
WO WO2004071404A2
· 2004
[cited by applicant]
WO WO2004073741A1
· 2004
[cited by applicant]
WO WO2004096273A1
· 2004
[cited by applicant]
WO WO2005028514A1
· 2005
[cited by applicant]
WO WO2005037315A1
· 2005
[cited by applicant]
WO WO2005044848A1
· 2005
[cited by applicant]
WO WO2005061000A1
· 2005
[cited by applicant]
WO WO2005080429A2
· 2005
[cited by applicant]
WO WO2005090405A1
· 2005
[cited by applicant]
WO WO2005107800A1
· 2005
[cited by applicant]
WO WO2006009092A1
· 2006
[cited by applicant]
WO WO2006023144A2
· 2006
[cited by applicant]
WO WO2006070286A2
· 2006
[cited by applicant]
WO WO2006072954A2
· 2006
[cited by applicant]
WO WO2006119115A2
· 2006
[cited by applicant]
WO WO2007043641A1
· 2007
[cited by applicant]
WO WO2007046489A1
· 2007
[cited by applicant]
WO WO2007058194A1
· 2007
[cited by applicant]
WO WO2007061029A1
· 2007
[cited by applicant]
WO WO2007067976A2
· 2007
[cited by applicant]
WO WO2007074880A1
· 2007
[cited by applicant]
WO WO2007076927A1
· 2007
[cited by applicant]
WO WO2007086490A1
· 2007
[cited by applicant]
WO WO2007114319A1
· 2007
[cited by applicant]
WO WO2007116962A1
· 2007
[cited by applicant]
WO WO2007137984A2
· 2007
[cited by applicant]
WO WO2007143168A2
· 2007
[cited by applicant]
WO WO2008020079A1
· 2008
[cited by applicant]
WO WO2008090901A1
· 2008
[cited by applicant]
WO WO2008144763A2
· 2008
[cited by applicant]
WO WO2009010539A2
· 2009
[cited by applicant]
WO WO2009014263A1
· 2009
[cited by applicant]
WO WO2009041613A1
· 2009
[cited by applicant]
WO WO2009041621A1
· 2009
[cited by applicant]
WO WO2009041643A1
· 2009
[cited by applicant]
WO WO2009044774A1
· 2009
[cited by applicant]
WO WO2009125825A1
· 2009
[cited by applicant]
WO WO2009148148A1
· 2009
[cited by applicant]
WO WO2010021697A2
· 2010
[cited by applicant]
WO WO2010035769A1
· 2010
[cited by applicant]
WO WO2010065078A1
· 2010
[cited by applicant]
WO WO2010106812A1
· 2010
[cited by applicant]
WO WO2010107108A1
· 2010
[cited by applicant]
WO WO2011013786A1
· 2011
[cited by applicant]
WO WO2011131749A1
· 2011
[cited by examiner]
WO WO2011149046A1
· 2011
[cited by applicant]
WO WO2011149051A1
· 2011
[cited by applicant]
WO WO2011154139A2
· 2011
[cited by applicant]
WO WO2012063875A1
· 2012
[cited by applicant]
WO WO2012064627A2
· 2012
[cited by applicant]
WO WO2012118750A2
· 2012
[cited by applicant]
WO WO2014200018A1
· 2014
[cited by applicant]
WO WO2016027859A1
· 2016
[cited by applicant]
WO WO2016104777A1
· 2016
[cited by applicant]
WO WO2016136933A1
· 2016
[cited by applicant]
WO WO2016186154A1
· 2016
[cited by applicant]
WO WO2018008750A1
· 2018
[cited by applicant]
WO WO2018203545A1
· 2018
[cited by applicant]
WO WO2019078344A1
· 2019
[cited by applicant]
WO WO2020117929A1
· 2020
[cited by applicant]
WO WO2020202839A1
· 2020
[cited by applicant]
WO WO2020213665A1
· 2020
[cited by applicant]
WO WO2022191306A1
· 2022
[cited by applicant]
WO WO2023095852A1
· 2023
[cited by applicant]
WO WO2023140269A1
· 2023
[cited by applicant]
Kazuhiro et al. Real-world effects of two inhaled corticosteroid/long-acting β2-agonist combinations in the treatment of asthma. The Journal of asthma : official journal of the Association for the Care of Asthma, Abstra…
[cited by examiner]
Saglani, S.Obesity, systemic inflammation and respiratory disease. Pediatric Pulmonology, (Jun. 2017) vol. 52, Supp. Supplement 46, pp. S89-S91. Abstract Number: #2. Meeting Info: 16th CIPP 2017. Lisbon, Portugal. Jun. …
[cited by examiner]
NCT02794519 (ClinicalTrials.gov. A phase 2a study to evaluate the effects of sirukumab in subject with severe poorly controlled asthma, pp. 1-23 (Jun. 2016). (Year: 2016).
[cited by examiner]
Ano et al. Transcription Factors GATA-3 and RORyt Are Important for Determining the Phenotype of Allergic Airway Inflammation in a Murine Model of Asthma. J Immunol vol. 190 (3): 1056-1065; (2013). (Year: 2013).
[cited by examiner]
ADIS R&D Profile. Atlizumab. Anti-IL-6 receptor antibody—Chugai, Anti-interleukin-6 receptor antibody—Chugai, MRA—Chugai. Biodrugs vol. 17 (5): 369-372, (2003) (Year: 2003).
[cited by examiner]
Neil C. Thomson. Novel approaches to the management of non-eosinophilic asthma. Therapeutic advances in respiratory disease. vol. 10(3):211-234 (2016). (Year: 2016).
[cited by examiner]
Edwards et al. The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. Journal of Molecular Biology 334:103-118; (2003). (Year: 2003).
[cited by examiner]
Lloyd et al. Modelling the human immune response: performance of a 10(11) human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Engineering, Eng. Design & Selection 22(3): 159-168…
[cited by examiner]
Goel et al. Plasticity within the antigen-combining site may manifest as molecular mimicry in the humoral immune response. J. Immunol. 173: 7358-7367; (2004). (Year: 2004).
[cited by examiner]
Khan et al. Adjustable locks and flexible keys: plasticity of epitope-paratope interactions in germline antibodies. J. Immunol. 192: 5398-5405; (2014) (Year: 2014).
[cited by examiner]
Poosarla et al. teach Computational De Novo Design of Antibodies Binding to a Peptide With High Affinity. Biotechn. Bioeng. 114(6): 1331-1342; (2017). (Year: 2017).
[cited by examiner]
Almand, B., et al., “Clinical Significance of Defective Dendritic Cell Differentiation in Cancer,” Clin Cancer Res., 6:1755-1766 (2000).
[cited by applicant]
Almand, B., et al., “Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer,” J Immunol., 166:678-689 (2001).
[cited by applicant]
Ano, S., et al., “Transcription Factors GATA-3 and RORγt Are Important for Determining the Phenotype of Allergic Airway Inflammation in a Murine Model of Asthma,” J Immunol., 190:1056-1065 (2013).
[cited by applicant]
346: Anti-IL-6 treatment in two pediatric patients with severe persistent asthma with the IL4R576 variant, Presentation, AAAAI/WAO Joint Congress, Mar. 2-5, 2018, Orlando, FL, USA, https://aaaai.confex.com/aaaai/wao18/w…
[cited by applicant]
ANZCTR, registered trial, Trial Review, Reg. No. ACTRN12614000123640, Registered Feb. 3, 2014.
[cited by applicant]
Araki, M., et al., “Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica,” Neurology, 82:1302-1306 (2014).
[cited by applicant]
Araki, M., et al., “Latest Treatments and Prospects for Neuromyelitis Optica,” The Medical Frontline, 71(6):1159-1167 (2016).
[cited by applicant]
Burska, A. N., et al., “Gene expression analysis in RA: towards personalized medicine,” Pharmacogenomics J., 14:93-106 (2014).
[cited by applicant]
Capelo, A. V., et al., “Visceral adiposity is associated with cytokines and decrease in lung function in women with persistent asthma,” Rev Port Pneumol., 22(5):255-261 (2016).
[cited by applicant]
Chu, D. K., et al., “Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma,” Allergy Asthma Clin Immunol., 11:14 (2015), 6 pages.
[cited by applicant]
ClinicalTrials.gov, “A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma,” ID: NCT02794519, Sponsored by GlaxoSmithKline, Jun. 9, 2016.
[cited by applicant]
Dall'Acqua, W. F., et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” J Biol Chem., 281(33):23514-23524 (2006).
[cited by applicant]
Doganci, A., et al., “The IL-6R a chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo,” J Clin Invest., 115(2):313-325 (2005).
[cited by applicant]
Feaver, R., et al., “The Anti-IL-6 Antibody Sirukumab Inhibits Vascular Inflammation in a Human Surrogate Model of Atherosclerosis,” American College of Rheumatology Meeting Abstracts, Abstract No. 439 (2014).
[cited by applicant]
Habara, T., et al., “The biological effects of antiadhesion agents on activated RAW264.7 macrophages,” J Biomed Mater Res., 61:628-633 (2002).
[cited by applicant]
Hashizume, M., et al., “IL-6 plays an essential role in neutrophilia under inflammation,” Cytokine, 54:92-99 (2011).
[cited by applicant]
Hashizume, M. and Ohsugi, Y., “IL-6 as a target in autoimmune disease and inflammation,” Folia Pharmacol Jpn., 144:172-177 (2014).
[cited by applicant]
Hisanaga, K., “Neuro-Behcet disease and neuro-Sweet disease,” Clin Neurol., 52:1234-1236, (2012), English abstract.
[cited by applicant]
Holmdahl, L., “The Role of Fribrinolysis in Adhesion Formation,” Eur J Surg., Suppl 577:24-31 (1997).
[cited by applicant]
Hong, D. S., et al., “Interleukin-6 and Its Receptor in Cancer,” Cancer, 110:1911-1928 (2007).
[cited by applicant]
Igawa, T., et al., “pH-dependent antigen-binding antibodies as a novel therapeutic modality,” Biochim Biophys Acta., 1844(11):1943-1950 (2014).
[cited by applicant]
Ishikawa, S., et al., “[SAT0079] DNA Microarray of SLE Related Genes That Respond to IL-6 Blockade with Tocilizumab an Anti-IL-6 Receptor Monoclonal Antibody,” Ann Rheum Dis., 65(Suppl II):474 (2006).
[cited by applicant]